Income Statement Shanghai RAAS Blood Products Co., Ltd.
Equities
002252
CNE100000C31
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.690 CNY | -0.18% |
|
+0.18% | -10.25% |
| Mar. 27 | RAAS Blood Products' 2025 Profit Slides 28%, Revenue Falls 10% | MT |
| Mar. 26 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 4.28B | 6.57B | 7.96B | 8.17B | 7.34B | |||||
Other Revenues, Total | 3.01M | 1.32M | 1.57M | 2.85M | 8.43M | |||||
Total Revenues | 4.29B | 6.57B | 7.96B | 8.18B | 7.35B | |||||
Cost of Goods Sold, Total | 2.07B | 3.68B | 4.73B | 4.87B | 4.66B | |||||
Gross Profit | 2.22B | 2.89B | 3.23B | 3.3B | 2.69B | |||||
Selling General & Admin Expenses, Total | 617M | 706M | 713M | 868M | 804M | |||||
Provision for Bad Debts | -11.97M | 15.19M | -5.3M | 43.64M | 20.41M | |||||
R&D Expenses | 129M | 146M | 174M | 251M | 223M | |||||
Other Operating Expenses | 23.05M | 32.81M | 31.52M | 48.65M | 46.54M | |||||
Other Operating Expenses, Total | 757M | 900M | 913M | 1.21B | 1.09B | |||||
Operating Income | 1.46B | 1.99B | 2.32B | 2.09B | 1.6B | |||||
Interest Expense, Total | -472K | -263K | -120K | -225K | -44.11M | |||||
Interest And Investment Income | 466M | 511M | 135M | 634M | 423M | |||||
Net Interest Expenses | 466M | 510M | 135M | 634M | 378M | |||||
Currency Exchange Gains (Loss) | 11.28M | -56.55M | -43.34M | -85.01M | 16.79M | |||||
Other Non Operating Income (Expenses) | -1.91M | -1.42M | -421K | -75.1K | -11.27M | |||||
EBT, Excl. Unusual Items | 1.94B | 2.44B | 2.41B | 2.64B | 1.98B | |||||
Impairment of Goodwill | -361M | -197M | - | - | -94.02M | |||||
Gain (Loss) On Sale Of Investments | -42.76M | 18.38M | -197M | - | - | |||||
Gain (Loss) On Sale Of Assets | -1.35M | 227K | -12.49K | -1.61M | 21.16M | |||||
Asset Writedown | -9.26M | -2.47M | -4.43M | -13.23M | 68.97K | |||||
Other Unusual Items | 16.54M | 13.11M | -2.37M | -7.08M | -1.73M | |||||
EBT, Incl. Unusual Items | 1.54B | 2.27B | 2.2B | 2.62B | 1.91B | |||||
Income Tax Expense | 250M | 401M | 427M | 426M | 329M | |||||
Earnings From Continuing Operations | 1.29B | 1.87B | 1.78B | 2.19B | 1.58B | |||||
Net Income to Company | 1.29B | 1.87B | 1.78B | 2.19B | 1.58B | |||||
Minority Interest | 5.56M | 7.09M | 2.04M | -499K | 419K | |||||
Net Income - (IS) | 1.29B | 1.88B | 1.78B | 2.19B | 1.58B | |||||
Net Income to Common Incl Extra Items | 1.29B | 1.88B | 1.78B | 2.19B | 1.58B | |||||
Net Income to Common Excl. Extra Items | 1.29B | 1.88B | 1.78B | 2.19B | 1.58B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.19 | 0.28 | 0.27 | 0.33 | 0.24 | |||||
Basic EPS - Continuing Operations | 0.19 | 0.28 | 0.27 | 0.33 | 0.24 | |||||
Basic Weighted Average Shares Outstanding | 6.74B | 6.74B | 6.69B | 6.65B | 6.58B | |||||
Net EPS - Diluted | 0.19 | 0.28 | 0.27 | 0.33 | 0.24 | |||||
Diluted EPS - Continuing Operations | 0.19 | 0.28 | 0.27 | 0.33 | 0.24 | |||||
Diluted Weighted Average Shares Outstanding | 6.74B | 6.74B | 6.69B | 6.65B | 6.58B | |||||
Normalized Basic EPS | 0.18 | 0.23 | 0.23 | 0.25 | 0.19 | |||||
Normalized Diluted EPS | 0.18 | 0.23 | 0.23 | 0.25 | 0.19 | |||||
Dividend Per Share | 0.03 | 0.03 | 0.03 | 0.07 | 0.05 | |||||
Payout Ratio | 13.02 | 10.04 | 11.36 | 20.05 | 16.4 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.61B | 2.17B | 2.47B | 2.29B | 1.82B | |||||
EBITA | 1.47B | 2B | 2.32B | 2.15B | 1.64B | |||||
EBIT | 1.46B | 1.99B | 2.32B | 2.09B | 1.6B | |||||
EBITDAR | 1.62B | 2.17B | 2.48B | 2.31B | 1.84B | |||||
Total Revenues (As Reported) | 4.29B | 6.57B | 7.96B | 8.18B | - | |||||
Effective Tax Rate - (Ratio) | 16.25 | 17.62 | 19.36 | 16.27 | 17.26 | |||||
Current Domestic Taxes | 260M | 381M | 424M | 422M | - | |||||
Total Current Taxes | 260M | 381M | 424M | 422M | 358M | |||||
Deferred Domestic Taxes | -9.67M | 19.62M | 2.88M | 3.84M | - | |||||
Total Deferred Taxes | -9.67M | 19.62M | 2.88M | 3.84M | -28.98M | |||||
Normalized Net Income | 1.22B | 1.53B | 1.51B | 1.65B | 1.24B | |||||
Interest Capitalized | - | - | - | - | 443K | |||||
Interest on Long-Term Debt | 442K | 263K | 120K | 225K | 771K | |||||
Non-Cash Pension Expense | 343K | 896K | 50.41M | 2.06M | 3.47M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 170M | 193M | 143M | 193M | 109M | |||||
Selling and Marketing Expenses | 306M | 373M | 334M | 408M | 335M | |||||
General and Administrative Expenses | 311M | 333M | 379M | 460M | 469M | |||||
Research And Development Expense From Footnotes | 129M | 146M | 174M | 251M | 223M | |||||
Net Rental Expense, Total | 4.91M | 8.42M | 8.98M | 13.11M | 23.41M | |||||
Imputed Operating Lease Interest Expense | 2.32M | 2.94M | 3M | 2.42M | 4.26M | |||||
Imputed Operating Lease Depreciation | 2.59M | 5.48M | 5.98M | 10.69M | 19.16M | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | 4.48M | 10.17M | 5.81M | |||||
Stock-Based Comp., S&M Exp. (Total) | - | - | 2.17M | 5.3M | 731K | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | 12.72M | 33.09M | 12.02M | |||||
Stock-Based Comp., Other (Total) | - | - | 2.23M | 5.21M | 1.24M | |||||
Total Stock-Based Compensation | - | - | 21.61M | 53.78M | 19.8M |
Select your edition
All financial news and data tailored to specific country editions
















